MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)

Piccart, M.Borrego, M. RuizArkenau, H-T.Escriva-De-Romani, S. I.Howell, S. J.Hennequin, A.Jimenez-Rodriguez, B.Del Conte, G.Simonelli, M.Palleschi, M.Duhoux, F.De Speville Uribe, B. DogerCurigliano, G.Waters, S.Aftimos, P. G.Wildiers, H.Tosi, D.Amair-Pinedo, F.Pellacani, A. U. E.Laurent, D. O.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/27098enMEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)conference outputopen access10.1016/j.annonc.2021.08.5491569-8041https://doi.org/10.1016/j.annonc.2021.08.549700527700245